Engineers Gate Manager LP acquired a new stake in Glaukos Corp (NYSE:GKOS) in the fourth quarter, HoldingsChannel.com reports. The fund acquired 59,725 shares of the medical instruments supplier’s stock, valued at approximately $1,532,000.
Other institutional investors and hedge funds have also recently made changes to their positions in the company. Shaker Investments LLC OH lifted its stake in shares of Glaukos by 6.3% during the 3rd quarter. Shaker Investments LLC OH now owns 47,025 shares of the medical instruments supplier’s stock worth $1,552,000 after buying an additional 2,800 shares during the last quarter. Arrowstreet Capital Limited Partnership lifted its stake in shares of Glaukos by 77.4% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 15,300 shares of the medical instruments supplier’s stock worth $634,000 after buying an additional 6,676 shares during the last quarter. Northern Trust Corp lifted its stake in shares of Glaukos by 15.1% during the 2nd quarter. Northern Trust Corp now owns 251,342 shares of the medical instruments supplier’s stock worth $10,424,000 after buying an additional 33,017 shares during the last quarter. Koch Industries Inc. acquired a new stake in shares of Glaukos during the 2nd quarter worth about $683,000. Finally, Wasatch Advisors Inc. acquired a new stake in shares of Glaukos during the 4th quarter worth about $661,000.
In other Glaukos news, CFO Joseph E. Gilliam acquired 2,100 shares of the company’s stock in a transaction on Wednesday, November 22nd. The stock was acquired at an average price of $23.84 per share, for a total transaction of $50,064.00. Following the purchase, the chief financial officer now directly owns 102,100 shares of the company’s stock, valued at $2,434,064. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 16.40% of the stock is owned by insiders.
Glaukos (NYSE:GKOS) last issued its quarterly earnings data on Tuesday, November 7th. The medical instruments supplier reported $0.04 earnings per share for the quarter, topping the consensus estimate of ($0.02) by $0.06. Glaukos had a negative net margin of 0.64% and a positive return on equity of 3.50%. The business had revenue of $40.41 million during the quarter, compared to analysts’ expectations of $38.69 million. During the same quarter in the previous year, the company earned $0.03 EPS. The business’s revenue was up 36.6% on a year-over-year basis. equities research analysts expect that Glaukos Corp will post -0.03 earnings per share for the current year.
A number of analysts have recently issued reports on the stock. BMO Capital Markets restated a “buy” rating and set a $45.00 target price on shares of Glaukos in a research note on Wednesday, October 18th. Cantor Fitzgerald restated a “buy” rating and set a $60.00 target price on shares of Glaukos in a research note on Tuesday, November 7th. Zacks Investment Research upgraded shares of Glaukos from a “sell” rating to a “hold” rating in a research note on Monday, November 13th. Stephens restated an “overweight” rating and set a $40.00 target price (down previously from $47.00) on shares of Glaukos in a research note on Monday, November 13th. Finally, ValuEngine cut shares of Glaukos from a “hold” rating to a “sell” rating in a research note on Monday. One analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the company’s stock. Glaukos has a consensus rating of “Buy” and an average price target of $44.86.
TRADEMARK VIOLATION WARNING: “Engineers Gate Manager LP Invests $1.53 Million in Glaukos Corp (GKOS)” was reported by Community Financial News and is owned by of Community Financial News. If you are accessing this report on another website, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://www.com-unik.info/2018/02/09/engineers-gate-manager-lp-invests-1-53-million-in-glaukos-corp-gkos.html.
Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm’s canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream.
Want to see what other hedge funds are holding GKOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Glaukos Corp (NYSE:GKOS).
Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.